Efavirenz Posaconazole 491

Clinical Bottom Line
Minimal data to guide interaction: risks likely to outweigh benefits
Drug 1
Drug 1 dose
400 mg BID x 10 and 20 days
Drug 1 effect

No significant change

Drug 2
Drug 2 dose
400 mg BID for 10 and 20 days
Drug 2 effect

Posaconazole AUC decreased 50%; Cmax decreased 45%

Clinical Effects

Decreased posaconazole effects

Management

Consider using alternative agents. If coadministering, dose adjustment has not been established

Import ID
491